1. Home
  2. Medical Research
  3. Houston, TX
  4. Cll Global Research Foundation

Cll Global Research Foundation

Cll Global Research Foundation is ranked #8 of 13 medical research organizations in Houston, TX, with an America's Best Score of 72 out of 100, based on its 2025 Form 990.

  • Houston, TX
  • Tax-exempt since 2004
  • EIN: 88-0517430
cllglobal.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
72OF 100 #8 of 13 in Houston ranked medical research organizations How this score is calculated

Organization summary

Cll Global Research Foundation is a 501(c)(3) organization, classified under Medical Research (NTEE H30). Contributions are tax-deductible.

1515 Holcombe Blvd Unit 428, Houston, TX 77030-4028

Among the 16 scored medical research organizations in Houston, Cll Global Research Foundation holds 28 months of operating reserves (peer median 17.8 months), runs a typical yearly deficit of 19.3% (peers: surplus of 4.9%), and has grown spending 22.7% a year (peers: grown spending 15.5% a year).

In fiscal year 2025 it reported $3,170,285 in revenue and $3,943,865 in expenses, with contributions making up 80.6% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

CLL Global's mission is to abolish chronic lymphocytic leukemia (CLL) as a threat to the life and health of patients by accelerating CLL research.

Largest programs · fiscal year 2025

  • RESEARCH GRANTS: The CLL Global Research Foundation's primary activity is to accelerate research. The need is urgent to accelerate promising, untapped areas of research. CLL Global provides grants through several mechanisms to fund novel, patient-oriented concepts. The intention is to fund the best CLL science in the world. In particular, CLL Global targets monoclonal antibodies, prognostic factor… Read more

    RESEARCH GRANTS: The CLL Global Research Foundation's primary activity is to accelerate research. The need is urgent to accelerate promising, untapped areas of research. CLL Global provides grants through several mechanisms to fund novel, patient-oriented concepts. The intention is to fund the best CLL science in the world. In particular, CLL Global targets monoclonal antibodies, prognostic factors, vaccines & gene therapy, CLL survival pathway, genetics, molecular targets, and drug development. Continued on Schedule O A Scientific Advisory Board (SAB) develops the research priorities and oversees the development and implementation of the submission, evaluation and funding process for grant application cycles. SAB members have extensive experience in treating CLL patients, developing new drugs and other tools, and studying various aspects of the disease. The research grant section also allows support of postdoctoral fellows conducting a CLL-specific project. In 2025, CLL Global awarded new research/individual grants ranging from $100,000-$250,000. Applicants intially submit proposals for grants up to $150,000 in funding for one year. Applicants identify project milestones. Upon demonstration of sufficient progress, investigators will be considered for a second year of funding. For accounting purposes, CLL Global expenses grants at the time of completion of a sponsored research agreement.

    $3,527,489 spent · 92.9% of program spending
  • ALLIANCE: The US/European Alliance for the Therapy of CLL (Alliance) is comprised of 20 individuals from the United States and Europe, representing the world's experts in CLL research. The members are divided into working groups focusing on one of five big ideas in CLL research (refractory disease, immune dysfunction and restoration, novel therapeutic targets and approaches, Richter's transformati… Read more

    ALLIANCE: The US/European Alliance for the Therapy of CLL (Alliance) is comprised of 20 individuals from the United States and Europe, representing the world's experts in CLL research. The members are divided into working groups focusing on one of five big ideas in CLL research (refractory disease, immune dysfunction and restoration, novel therapeutic targets and approaches, Richter's transformation, high risk and genomically complex disease). The Alliance was built to encourage close collaboration between and among working groups. As such, meetings are held annually to bring investigators together to collaborate.

    $242,980 spent · 6.4% of program spending
  • EDUCATION: CLL Global Research Foundation hosts annual interactive patient education events where CLL patients learn about emerging therapies, current treatment options and support resources from leading CLL experts. Events are recorded and recordings made available on the foundation's website. Three events were held in 2025. $25,000 spent · 0.7% of program spending

Where each dollar went · fiscal year 2025

Of every dollar it spent, 96¢ went to programs, 3¢ to management and 1¢ to fundraising.

  • Programs $3,795,469
  • Management $105,125
  • Fundraising $43,271

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score72 / 100
Rank in Houston#8 of 13
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves28.0 mo; 7.7 mo in cash19.4 / 25
Financial balance (median margin)−19.3%0 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth+22.7% / yr15 / 15
Track record22 years8.8 / 10
Debt load15.8% of assets8.8 / 10
Total72.1 → 72
Spending on programs
Not scored; America's Best needs 65%+
96%Meets

Compared with Houston peers

MeasureThis organizationPeer median
Operating reserves28.0 mo17.8 mo
Typical margin−19.3%+4.9%
Spending growth+22.7% / yr+15.5% / yr
Debt load15.8%6.6%

Peers: the 16 Houston medical research organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$3,170,285Fiscal year 20252022: $1,719,45120222023: $2,535,60920232024: $3,057,83520242025: $3,170,2852025
Expenses$3,943,865Fiscal year 20252022: $2,136,72420222023: $3,129,58920232024: $3,450,54220242025: $3,943,8652025
Total assets$10,922,467Fiscal year 20252022: $10,938,77220222023: $12,019,24620232024: $11,594,43420242025: $10,922,4672025
Total liabilities$1,728,136Fiscal year 20252022: $2,088,71620222023: $2,876,85820232024: $2,181,29020242025: $1,728,1362025
Fiscal year ending December 2025
Revenue$3,170,285
Expenses$3,943,865
Net income−$773,580
Net assets$9,194,331

Notable sources of revenue

Percent of total revenue
Contributions$2,554,060
Program services$0
Investment income$616,225
Other (net)$0

Assets / debt

Total assets$10,922,467
Total liabilities$1,728,136
Net assets$9,194,331

Compensation

Not in our extract for this year.

Fiscal year ending December 2024
Revenue$3,057,835
Expenses$3,450,542
Net income−$392,707
Net assets$9,413,144

Notable sources of revenue

Percent of total revenue
Contributions$2,608,606
Program services$0
Investment income$449,229
Other (net)$0

Assets / debt

Total assets$11,594,434
Total liabilities$2,181,290
Net assets$9,413,144

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$2,535,609
Expenses$3,129,589
Net income−$593,980
Net assets$9,142,388

Notable sources of revenue

Percent of total revenue
Contributions$2,469,879
Program services$0
Investment income$65,730
Other (net)$0

Assets / debt

Total assets$12,019,246
Total liabilities$2,876,858
Net assets$9,142,388

Compensation

Not in our extract for this year.

Fiscal year ending December 2022
Revenue$1,719,451
Expenses$2,136,724
Net income−$417,273
Net assets$8,850,056

Notable sources of revenue

Percent of total revenue
Contributions$2,693,348
Program services$0
Investment income$131,862
Other (net)−$1,105,759

Assets / debt

Total assets$10,938,772
Total liabilities$2,088,716
Net assets$8,850,056

Compensation

Officers and key employees$40,000
Share of expenses1.9%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?